Dr. Fleisher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
893 Delaware st
Indianapolis, IN 46225Phone+1 317-653-0370
Education & Training
- Johns Hopkins UniversityResidency, Neurology, 1999 - 2002
- Johns Hopkins UniversityInternship, Internal Medicine, 1998 - 1999
- University of Rochester School of Medicine and DentistryClass of 1998
Certifications & Licensure
- AZ State Medical License 2008 - 2025
- IN State Medical License 2018 - 2025
- CA State Medical License 2002 - 2015
- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 145 citationsA multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.Michael J. Pontecorvo, Michael D. Devous, Ian Kennedy, Michael Navitsky, Ming Lu
Brain. 2019-06-01 - 215 citationsBasal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology.Taylor W. Schmitz, R. Nathan Spreng, Michael W. Weiner, Paul S. Aisen, Ronald C. Petersen
Nature Communications. 2016-11-04 - 779 citationsUse of Florbetapir-PET for Imaging β-Amyloid PathologyChristopher M. Clark, Julie A. Schneider, Barry J. Bedell, Thomas G. Beach, Warren B. Bilker
JAMA. 2011-01-19
Journal Articles
- Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairm...Stephen P Salloway, Jennifer A Zimmer, Adam S Fleisher, JAMA Neurology
Press Mentions
- Alzheimer's Pathology, Tangles Predicted by Tau PETApril 27th, 2020
- Associations of Regional Brain Structural Differences with Aging, Modifiable Risk Factors for Dementia, and Cognitive PerformanceDecember 2nd, 2019
- Association of Altered Liver Enzymes with AD, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid BiomarkersJuly 31st, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: